Under construction – not a live service
Sign in
Taking people in NorwayNo phase

The Remote Monitoring of Gout Feasibility Study in Primary Care

Key facts

Where
Oslo, NorwaySee the site

Where in Norway

  • Diakonhjemmet HospitalOslo, NorwayContact: Fiona Aanesen, PhDTaking people

Questions to ask the study team

  1. How often do I need to come in, and for how long each time?
  2. Are travel costs paid?
  3. Can I keep my own doctor?
  4. What happens if I want to stop?

Contact the study team: see the registry record → Contacts and Locations

Print a page for my doctor

Trial details

Who runs it
Diakonhjemmet Hospital
Trial code
NCT07490522
Record updated
30 April 2026
Original description
The goal of this feasibility study is to determine the feasibility of a patient self-management app (MinUrinsyregikt) for patients with gout. The primary objectives of the study are:Read full original descriptionShow less

The Self-management App 'MinUrinsyregikt' for Patients With Gout. The ReMonit Gout Feasibility Study in Primary Care

The goal of this feasibility study is to determine the feasibility of a patient self-management app (MinUrinsyregikt) for patients with gout. The primary objectives of the study are:

1. To determine the feasibility of a patient self-management app for patients with gout receiving GP follow-up. 2. To determine the feasibility of conducting a future randomised controlled trial to test the effectiveness of the app for patients with gout in primary care.

Participants will be asked to test the self-management app for 3 months. Data will be collected from the participants and their GPs.

Patients are eligible to be included in the study only if all the following criteria apply:; Adults ≥18 years of age at screening; Patients with a clinical diagnosis of gout; Serum urate level >360 µmol/L at inclusion; Indication for urate lowering therapy assessed by medical doctor; Having a smartphone/tablet; Patients are excluded from the study if any of the following criteria apply:; Pregnant or breastfeeding; Contraindication for urate lowering therapy; Does not understand Norwegian language; Major co-morbidities (e.g., malignancies, severe chronic kidney disease, severe mental disorders).

ClinicalTrials.gov NCT07490522